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introduction
Interest in the integration of “genomic medicine” into routine 
medical care is rapidly increasing, given the association of 
genetic variation with disease risk, development and progres-
sion of somatic diseases and of cancer, and drug efficacy or risk of 
adverse events.1 The core technology is termed “next- generation 
sequencing” (NGS), broadly defined as gene sequencing using 
massively parallel strategies. The first publication on the use of 
this technology was in 2005,2 in which sequencing of 25 million 
bases at 99% or better accuracy in one 4-hour run was able to 
achieve an approximately 100-fold increase in throughput over 
existing Sanger sequencing technology. Nine years later, NGS 
has found applications in sequencing the genome, exome, tran-
scriptome, and microbiome, with more than 6,000 citations in 
PubMed using this technology and >100 publications accruing 
per month.3
Initial citations consisted of single reports of NGS being 
applied to diagnose conditions for which conventional molecu-
lar methods had failed4 or for which known diseases (usually 
cancer) were resistant to established pharmacologic thera-
pies.5 Broader case-based experience is now forthcoming that 
  supports the concept that genomic testing can benefit patients 
with undiagnosed disorders whose management has exhausted 
all standard care options.6 Nevertheless, expansion of NGS 
utilization for more routine use still requires establishment of 
an evidence base for most clinical applications.7,8 Achieving this 
goal will require access to extensive information about patient 
genotype, clinical phenotype, treatment outcomes, and the eco-
nomics of delivering health care informed by genomic infor-
mation.9 Regardless, having “genomic medicine” available now 
is increasingly becoming a mark of leading health systems,10 
based on the premise that efficiency of health-care delivery and 
quality of life will be improved for their patients.11,12
The decision to bring NGS and genomic medicine into the 
clinical armamentarium is challenging because the actual clini-
cal evidence base for systematic use of this technology is not 
firmly established. Such decision making is made more diffi-
cult by substantial uncertainty in how use and interpretation of 
this technology will be paid for, both by federal programs and 
by private payers.13 Obtaining regulatory approval for clinical 
application of this technology, as through Clinical Laboratory 
Improvement Amendments certification, is also a barrier that 
to date only a few laboratories have cleared.
The Personalized Health Care Committee of the College of 
American Pathologists is tasked with examining the role of 
new technologies for molecular diagnostics and advising the 
College on policies and programs to support the implemen-
tation of such technologies. A seven-person workgroup was 
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Purpose: The practice of “genomic” (or “personalized”) medicine 
requires the availability of appropriate diagnostic testing. Our study 
objective was to identify the reasons for health systems to bring 
next-generation sequencing into their clinical laboratories and to 
understand the process by which such decisions were made. Such 
  information may be of value to other health systems seeking to pro-
vide next-generation sequencing testing to their patient populations.
Methods: A standardized open-ended interview was conducted 
with the laboratory medical directors and/or department of pathol-
ogy chairs of 13 different academic institutions in 10 different states.
results: Genomic testing for cancer dominated the institutional 
decision making, with three primary reasons: more effective delivery 
of cancer care, the perceived need for institutional leadership in the 
field of genomics, and the premise that genomics will eventually be 
cost-effective. Barriers to implementation included implementation 
cost; the time and effort needed to maintain this newer testing; chal-
lenges in interpreting genetic variants; establishing the bioinformat-
ics infrastructure; and curating data from medical, ethical, and legal 
standpoints. Ultimate success depended on alignment with institu-
tional strengths and priorities and working closely with institutional 
clinical programs.
conclusion: These early adopters uniformly viewed genomic analy-
sis as an imperative for developing their expertise in the implementa-
tion and practice of genomic medicine.
Genet Med advance online publication 10 July 2014
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commissioned to examine the business arguments for clinical 
use of NGS. Given the lack of published information regarding 
institutional implementation of NGS, the workgroup endeav-
ored to identify the reasons for health systems choosing to 
bring NGS into their clinical laboratories and to understand the 
process by which such decisions were made. Interviews of the 
laboratory directors for institutional “early adopters” of NGS 
technologies were conducted. The interviews covered reasons 
for establishing NGS testing within a health system (as opposed 
to using a reference laboratory), the process for making such 
a decision, barriers to bringing such testing in-house, lessons 
learned, and key drivers of success. This study is complemen-
tary to a recently published study that examined challenges 
and barriers in instituting genomic medicine from the perspec-
tive of institutional clinical leadership.14 Taken together, these 
studies provide valuable information for current and future 
institutional leaders, laboratory and clinical alike, considering 
establishment of genomic testing programs.
MAteriALs And MetHods
selection of participants
“Early adopter” health systems were identified by the following 
criteria: (i) having members serving on the College of American 
Pathologists “Personalized Health Care Committee”; (ii) perform-
ing NGS testing for human diagnostics under a Clinical Laboratory 
Improvement Amendments license; (iii) a record of peer-review 
publication documenting the use of massively  parallel sequencing 
for human laboratory diagnostics; and/or (iv) institutional public 
announcements of NGS implementation. We excluded for-profit 
laboratories or independent laboratory networks based on the 
premise that there was an inherent business argument for their 
performing NGS testing as reference laboratories. Rather, health 
systems were considered to constitute the “end users” of genomic 
information and, in choosing to perform NGS testing themselves, 
faced the more complex   decision-making process. By these inclu-
sion criteria, interviews of pathologist leaders from 13 academic 
medical centers were conducted. All prospects accepted the invi-
tation to be interviewed.
survey instrument
A 1-hour telephone interview was designed, using open-ended 
questions to give the interviewees an opportunity for discus-
sion. Approximately 1 week before the interview, a standardized 
list of 10 questions was sent to the interviewee. All interviews 
were conducted by one interviewer (J.H.K.) and were recorded. 
The 10 core questions were covered in the interview; for the 
purposes of elaboration, the core questions were supplemented 
by subquestions during the interview (the full set of questions 
and subquestions is given in Supplementary Table S1 online). 
This adaptive process allowed us to gain deeper insights into 
our core question areas.
data compilation and analysis
The complete interview transcripts were redacted to remove 
information that could potentially identify a given institution 
or individual. The word count for each institutional response 
was used as an initial measure of the information content,15,16 
with results presented in Table 1. Data were then analyzed 
according to qualitative content analysis.17,18 This methodology 
is appropriate for qualitative studies using open-ended inter-
views because it enables identification and quantification of 
specific concepts mentioned by respondents.19–21
resuLts
survey metrics
Thirteen institutions fulfilled one or more of the inclusion cri-
teria; these were located in 10 different states and one Canadian 
province. Two of the US institutions had Clinical Laboratory 
Improvement Amendments certification for clinical use of 
NGS technologies. Table 1 shows the rank order of word count 
for the 10 interview questions. There was no statistical differ-
ence in word count (data not shown) in relation to whether the 
individual being interviewed was the medical director of the 
molecular diagnostics laboratory (six interviews) or a pathol-
ogy department chair (five interviews) or if the department 
chair was invited to join the medical director in the interview 
(two interviews).
The greatest information content pertained to   prospective 
department and institutional decision making (question  1); 
only limited information was given about strategies for mea-
suring outcomes (question 9). This relative lack of content in 
response to the latter is telling because institutions had to make 
their decisions about implementing NGS in the absence of a pri-
ori evidence about whether doing so would help them achieve 
improved metrics for more efficient health care and/or better 
table 1  Rank order of answers by word count
Question
Word count: mean ± sd 
(range)
1.   Why did your institution decide to 
adopt NGS?a
1,318 ± 598 (533–2,162)
2. How did you implement NGS? 705 ± 337 (340–1,538)
6.   What are your plans for engaging 
payers in reimbursement for NGS?
455 ± 242 (75–710)
8.   What lessons learned can you share 
with future adopters of NGS?
294 ± 238 (120–1,038)
10.   What can the College of American 
Pathologists do to assist NGS 
adopters?
294 ± 180 (1–639)
7.   Are NGS services considered a 
competitive advantage?
266 ± 169 (43–672)
4.   How did you decide between 
in-house versus send-out NGS 
testing?
195 ± 180 (62–607)
5. How did you obtain funding for NGS? 110 ± 97 (6–307)
9.   How will you measure successful 
outcomes of adopting NGS?
103 ± 69 (6–228)
3.   What clinical applications did you 
choose for NGS?
79 ± 108 (18–413)
Total word count per institution 3,802 ± 1,528 (2,076–6,421)
NGS, next-generation sequencing.
aCollege of American Pathologists.
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patient outcomes. That being said, respondents spoke about (i) 
the ability to identify druggable targets in cancer; (ii) elimina-
tion of redundant testing; (iii) earlier diagnosis; (iv) growth in 
laboratory test volumes and expansion of testing menus; (v) 
achieving “better educated” clinicians and pathologists; (vi) 
increased interactions between the clinical laboratory and 
treating clinicians; (vii) assessment of provider satisfaction with 
laboratory support of patient care; and (viii) achievement of a 
self-sustaining financial model.
clinical applications and intended time line for 
deployment
Ten institutions indicated cancer genomics to be the primary 
clinical application for NGS testing. For the remaining three 
institutions, medical genetics was the primary application. 
Four institutions currently offered NGS testing clinically, seven 
institutions were looking to deploy NGS testing within the next 
6 to 12 months, for one institution the time line for deploy-
ment was uncertain, and one institution used send-out testing 
to offer genomic testing. Regardless of the initial intent, five of 
the seven institutions that gave estimates of relative target case 
volumes assumed that they would be performing NGS testing 
for both cancer genomics and medical genetics. The remaining 
two assumed that 100% of their NGS testing would be for can-
cer genomics. One institution also planned on branching out 
into NGS testing for infectious disease diagnostics.
drivers for implementation
Table 2 shows the reasons given for deciding to perform clini-
cal genomic testing, which are listed in order of decreasing 
frequency of mention. Institutions frequently gave multiple rea-
sons. Clinical demand and anticipated testing efficiency were 
almost uniform reasons. A critical indicator was genomic test-
ing that was already being “sent out” to a reference laboratory, 
which could be redirected to an in-house facility if established. 
This argument was even more compelling as the number of dif-
ferent tests being ordered increased, constituting the reason for 
performing one larger gene panel in-house. Because the testing 
platform is not gene or disease specific, testing could be con-
solidated. For only one institution was recruitment of oncolo-
gists (“cancer folks”) mentioned as a reason for deploying NGS 
sequencing. None of the respondents mentioned retention of 
personnel as a reason for bringing NGS testing in-house.
the institutional decision-making process
In 10 of the 13 institutions, officers above the level of depart-
ment chair were involved in review and approval of the decision 
to implement NGS testing, up to the level of the university pres-
ident (one institution) and chief operating officer of the hospital 
(five institutions). In two institutions, the dean of the college 
of medicine was a key decision maker, and in one institution, 
the cancer center director. In only three institutions the chair of 
the department of pathology was the senior institutional officer 
making the decision.
institutional funding
Twelve institutions commented on the sources of funding for 
bringing NGS in-house. For five institutions, 100% of the fund-
ing was from the hospital. For five other institutions, funding 
was entirely from the department of pathology, either entirely 
as research funds (one department) or as a mixture of research 
and department funds (four departments). It was for three of 
these latter five institutions that the decision-making process 
had been entirely controlled by the pathology department chair. 
In one institution, the department, hospital, and cancer center 
contributed equally to the implementation of NGS testing; this 
was the institution that involved the cancer center director in 
the decision-making process. Finally, one Canadian institution 
noted that funding for their NGS initiative was, ultimately, gov-
ernmental because the Canadian government supports both 
research and the clinical delivery system.
interactions with payers
For the four institutions already offering NGS testing, each had 
established mechanisms to work with payers for reimburse-
ment; one institution also relied heavily on reimbursement 
through “institutional accounts” in which the client institutions 
paid the NGS testing laboratory through reference laboratory 
agreements. These four respondents noted that agreements 
between their institution and specific payers or client institu-
tions were specific to their local environment and that these 
might not be applicable to other institutions.
table 2  Reasons for deciding to offer in-house genomic 
testing in the clinical practice setting
reason
number of 
institutions
Demand from clinical colleagues 13
Anticipated efficiency of NGS testing over conventional 
methods
12
Desire to gain institutional expertise in the technologies 
and in informatics
9
Desire to advance the clinical application of “personalized 
medicine”
7
Perceived requisite for institutional and departmental 
stature
5
Value for research 5
Improved turnaround time for molecular diagnostics 4
Desire to develop expertise before NGS becomes a 
commodity
3
Desire to have NGS expertise in-house for training and 
research
3
Retention of institutional control over cost, turnaround 
time, and validation
3
Desire for pathologists to provide leadership in clinical 
care
2
Competitive market advantage 2
Belief that overall cost of clinical care would be reduced 2
Difficulty of coordinating outsourced and in-house test 
results
1
Loss of research potential when outsourced 1
Recruitment of oncologists and cancer researchers 1
NGS, next-generation sequencing.
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Potential competitive value
Twelve of the 13 institutions were firm in their conviction that 
the availability of NGS testing constituted a competitive market 
advantage, both for their institutions as a whole and for their 
cancer centers. For four institutions, expansion of geographic 
reach of their health system constituted an additional perceived 
value. As one respondent stated, NGS testing was viewed as 
having a “halo effect” on the overall stature of the institution 
and its cancer center. The last institution considered that the 
clinical utility of NGS testing was not sufficiently established, so 
that the competitive value was as yet uncertain.
The question can be asked of whether competitive market 
advantage is an appropriate justification for implementing NGS 
testing. A starting point for this issue is performance of NGS 
testing in-house. “The whole reason for doing this is to be able 
to provide the same or often better service than the single gene 
test, at substantially lower costs.” Further, “In our practice envi-
ronment, the standard of care for certain malignancies [can be 
met] faster and cheaper by NGS, than by doing those panels of 
genes by Sanger sequencing.” “It is not about the sequencing 
machine. It is about the cost-per-test.” Beyond that, and even 
drawing on only case-based experience, “avoidance of futile 
therapeutic regimes is a powerful argument for the use of NGS 
testing.” This translates into oncologists “no longer planning 
treatments based on one particular gene test, but on a number 
of different genetic abnormalities.” 
institutional expectations
Only four respondents commented on institutional expec-
tations for outcomes as factoring into the decision-making 
process. These were enrolling patients in clinical trials (two 
institutions) and obtaining grant funding (one institution). The 
fourth institution did not expect financial sustainability for at 
least 5 years.
Barriers to implementation
Although only one survey question asked about “lessons 
learned” (question 8), sprinkled throughout the interview 
transcripts were comments about encountering and overcom-
ing barriers to NGS implementation and encountering unan-
ticipated needs (Table 3). A recurrent theme in the interviews 
was the challenge of having adequate institutional expertise in 
informatics. The two institutions with large existing research 
programs in genomics obtained valuable mentorship in starting 
up the bioinformatics for clinical genomics. Two other insti-
tutions were successful in recruiting experts in both genomic 
testing and informatics. Such recruitment was acknowledged 
as a significant barrier to overcome because “these people are 
in demand, and they will have competing job offers.” These two 
institutions spoke in glowing terms about the positive effect of 
these experts on the institution. By contrast, two other institu-
tions noted that they obtained institutional funding for equip-
ment acquisition but not the resources for recruitment, staff 
training, or equipment validation in order to get NGS opera-
tional. Not surprisingly, these two institutions were not yet 
operational for their NGS testing.
Lessons learned
Each institution offered its own lessons learned, with substan-
tive overlap among institutions (Table 4). Common themes 
were that implementation took or was taking longer, and 
table 3  Barriers to deployment of genomic testing and 
unanticipated needs
issue
number of 
institutions
Barriers
  Scarcity of informatics expertise 7
  Rapidly changing nature of technologies 4
  Validation of clinical testing protocols 3
  Expense of implementation 3
  Amount of data to curate 2
  Difficulty of getting first application deployed 2
    Ethics of reporting “all data” as opposed to “clinically 
indicated data”
2
    Lack of institutional resourcing of staff on-the-job 
training
2
  Uncertainty of reimbursement 1
  Uncertainty of clinical utility 1
Unanticipated needs
    Need for additional on-the-job training for 
technologists
8
  Need for training of pathologists and clinical scientists 5
  Need to develop staff and professional expertise 5
    Need for a full-time next-generation sequencing 
project manager
2
  Need for additional institutional IT resources 1
    Need for a multidisciplinary institutional governance 
committee
1
IT, information technology.
table 4  Lessons learned from implementing NGS testing
Lesson learned
number of 
institutions
Deployment was more complicated than anticipated (and 
took longer)
4
Need a more complete multidisciplinary team 4
Need to start with known testing applications before 
building further
4
Need to understand the market and anticipated clinical 
testing load
2
Need to play to institutional strengths in clinical 
programming
2
Need to verify adequacy of bioinformatics (analytics) 2
Need to be adequately capitalized and not build 
piecemeal
2
Need to have a local research laboratory as a partner 1
Need to have a multidisciplinary stakeholder advisory 
group
1
Need to specify patient selection for performance of NGS 
testing
1
NGS, next-generation sequencing.
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required more thorough involvement of clinical stakeholders, 
than anticipated. Four institutions started with a commercially 
established testing application before expanding into a broader 
test menu. Ironically, even for cancer-oriented institutions, 
germ-line testing for medical genetics was a plausible initial 
application for NGS so as to gain initial expertise and validate 
testing platforms. A related recommendation was to make sure 
that the chosen NGS testing aligned well with institutional 
strengths in clinical expertise, research programming, and, if 
available, informatics. This would help ensure that clinical case 
volumes would justify the performance of relevant NGS testing 
in-house. A second institution reported on the need to have a 
multidisciplinary advisory group to establish clear guidelines 
for which patients should be offered NGS testing as a lesson 
learned.
In the respondents’ words, these are additional thoughts 
about achieving success:
•	 “If you are a small place, wait for (i) the platforms, infor-
matics, and reporting to be worked out, and (ii) for 
research to demonstrate that [NGS] is clinically useful 
and superior. [From an implementation standpoint], you 
are better off if you can wait until NGS is pre-packaged, 
but then you will not be a leader in the field.” 
•	 “If you are going to be a leader, the greatest barrier is opti-
mizing the design of the gene panel for the clinical appli-
cation. These panels must be tested and validated before 
clinical implementation.” 
•	 “It is a lot easier to generate the data than [to] interpret it. 
You have to adequately resource the informatics function 
for interpretation. If you don’t, you end up with a very 
expensive paper weight in your department.” 
•	 “It is important to be adequately capitalized when you 
start. Trying to build NGS in a piecemeal fashion is not a 
successful strategy.” 
•	 “You must do high quality DNA extractions.” 
•	 “You have to work closely with clinical colleagues, so as to 
avoid offering something that will not be useful to their 
clinical practice. Match your platform with the testing 
that is needed.” 
•	 “Start small. Build your volume gradually so that you 
keep your quality up.” 
•	 “Understand the limitations of the technology. For testing 
specific small regions of the genome, NGS may not be the 
preferred technology.” 
•	 “Decide what data will be reported. Will you report infor-
mation that is not being tested for?” 
Measurement of outcomes
Intended evaluation of the outcomes of instituting NGS testing 
was qualitative in nature, along the lines of better management 
of patients (five institutions) and earlier clinical diagnosis (two 
institutions). When mentioned, intended quantitative mea-
sures included growth in test volumes, expansion in test menus, 
and elimination of other laboratory testing (four, two, and one 
institutions, respectively). Surveys were planned to assess phy-
sician and/or patient satisfaction (one institution each). In two 
institutions, achievement of a financially sustainable model was 
viewed as a key outcome measure.
Assistance from organized pathology
The respondents gave strong suggestions for contributions 
that could be made by the College of American Pathologists. 
Education of the professional and technical workforce for 
the performance of NGS testing was most frequently men-
tioned (seven institutions), followed by core activities of the 
College’s Laboratory Accreditation Program (testing stan-
dards, validation protocols, checklists, and proficiency testing). 
Dissemination of information about coding, billing, and reim-
bursement, as well as about national data networks and data-
bases was mentioned by more than one institution.
strategies for implementation
Three general strategies emerged for the implementation of 
NGS testing in-house: (i) overlaying NGS testing on established 
institutional polymerase chain reaction–based testing, before 
expanding the test menu; (ii) beginning with commercially 
validated NGS testing platforms, before expanding the test 
menu; (iii) starting with customized (but limited) NGS panels 
for specific applications, before expanding the test menu. An 
alternative to these is making the decision ab initio to out-
source NGS testing. In this last instance, a derivative decision 
is then whether to have the genomic analysis also performed on 
an outsourced basis or to perform the informatics analysis in-
house. The relevant value of each starting point is determined 
by local institutional needs and priorities. In turn, the timing 
and scope of expansion in available NGS test menus and appli-
cations will be determined in part by the success of the initial 
implementation and by the continued evolution of institutional 
strategies and priorities.
Proposed flowchart for institutional decision making and 
implementation
These survey responses permit the construction of a proposed 
flowchart for the institutional process of bringing NGS testing 
in-house (Figure 1). Although each institution will have its 
own unique requirements, this flowchart attempts to capture 
the essential elements for institutional decision making and 
project management.
discussion
The institutional decision to implement massively parallel 
sequencing, as exemplified by NGS, presents both an oppor-
tunity and a challenge. Because NGS testing is performed by 
a clinical laboratory, we surveyed the laboratory leaders, who 
carry ultimate responsibility for the validity of such testing. 
Whether medical director of a molecular diagnostic laboratory 
or department chair, these individuals are pathologists: physi-
cians who are experts in the performance, interpretation, and 
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clinical application of laboratory diagnostics. For these respon-
dents, institutional demand and the challenges of implementa-
tion were the primary issues to be faced.
As a dominant initiating theme, demand for NGS testing 
from clinical colleagues most often originated with oncolo-
gists. An equally dominant theme was the expectation that 
massively parallel NGS testing would, ultimately, be more effi-
cient than single test–based methodologies. That being said, a 
critical early decision was whether to implement custom panels 
or to implement commercially available testing products. The 
former permits tailoring of the panels to specific institutional 
needs; the latter enables implementation of testing that already 
has been validated elsewhere. Recommendations were made in 
favor of each starting strategy.
Returning to the question of whether “competitive advan-
tage” or “recognition” is a justifiable reason for implement-
ing NGS, there are a number of convergent considerations. 
Synthesizing their many responses, the institutions choosing 
to implement NGS sequencing (i) wished to attract patients to 
their institution; (ii) have both outstanding clinicians and labo-
ratorians for the practice of genomic medicine; (iii) contribute 
to new knowledge about the efficacy of NGS testing in patient 
care; and (iv) control costs, testing algorithms, and the quality 
of NGS testing. In the eyes of these institutions, acknowledging 
that “recognition” and “competitive advantage” might also be 
forthcoming is not so much justification as important collateral 
for being an institution that advances innovation in health care.
The reported barriers and challenges in implement-
ing NGS testing begin with having insufficient institutional 
expertise in informatics and in the technical performance of 
testing. Additional issues included the need for test valida-
tion, competent performance and interpretation of the test-
ing, determination of test utility, and financing, both of the 
initial implementation and of the ongoing testing program. 
Collectively, these issues reflect the unique requirements 
imposed by the regulatory environment for performing clini-
cal testing22 as opposed to testing that is done for research pur-
poses.23 These barriers and challenges are distinctly different 
from the institutional challenges reported by Manolio et al.,14 
which were limited evidence or consensus for which genomic 
variants were medically relevant; lack of reimbursement for 
genomically driven clinical interventions (which is different 
from concern about reimbursement for the performance of the 
genomic testing); and burden to patients and clinicians not only 
in assaying and reporting of testing but also in intervening and 
following up on genomic findings.
There was commonality in one challenge found by us and 
reported by Manolio et al.,14 which for our study respondents 
was the amount of data that needed to be curated and for 
respondents in the Manolio study was the need for a frame-
work to define and catalog clinically actionable genomic vari-
ants. Key for establishing such a framework is a knowledge 
base that captures sequence variants and their phenotypic asso-
ciations.14,24 It is therefore notable that a separate workgroup of 
the College of American Pathologists Personalized Healthcare 
Committee is currently examining the principles and specifi-
cations for   “clinically actionable” genomic databases, and the 
actual creation and curation of such databases is a pan-industry 
effort. That being said, the presence of such databases is only 
an intermediate step. Professional interpretation of genomic 
Figure 1   schematic for institutional decision making and project strategy.
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variants found during testing on individual patients must occur, 
and it is this step that constitutes the practice of medicine. The 
finalization of a test report requires both access to appropriate 
genomic databases and judgment of the clinical importance of 
test findings for the individual patient.
Regarding reimbursement for NGS testing, the four laborato-
ries already performing NGS testing had established reportedly 
productive conversations with payers, and six other laboratories 
in the process of implementation were optimistic about com-
munication with payers. One institution had well-  established 
payment mechanisms through interinstitutional agreements. 
With that one exception, institutions were not expecting finan-
cial sustainability of their NGS testing in the near future, and 
consumption of institutional resources, including research 
funds, was a necessary requirement for ongoing performance 
of such testing. This simple fact underscores the difficulty fac-
ing institutions in deciding whether or not to implement NGS 
testing.
This report highlights the challenges of instituting NGS 
testing, in the form of the need for additional institutional 
resources, and the diversity of unexpected issues. A theme that 
overlaps with the Manolio study is the highly multidisciplinary 
nature of implementing genomic testing.14 A corollary is iden-
tified in this study: the NGS testing chosen should align with 
institutional strengths both in clinical programming and in 
research initiatives. We note that, in more than 38,000 words 
of interview content, the word “governance” was mentioned 
only twice, once as an unanticipated additional requirement for 
implementation and once as a lesson learned after implemen-
tation. We have incorporated the requirement for governance 
as a requirement ab initio for implementing genomic medicine 
(Figure 1). We also recommend that the patient voice be rep-
resented in such a governance mechanism because genomic 
medicine not only cuts across technical practice and medical 
management but also invokes ethical and societal issues.6,25
The limited information content for assessment of outcomes 
was striking. Establishment of quantitative metrics is imme-
diately possible for test volume, test menu, and financial sus-
tainability, and it is achievable for physician satisfaction and 
patient satisfaction through survey mechanisms. However, the 
actual assessment of health-care outcomes remains elusive. 
The relative paucity of institutional specifications for assessing 
outcomes challenges the establishment of an evidence base for 
the presumed clinical utility of genomic medicine. We consider 
setting up the metrics prospectively for quantitative assessment 
of patient and population outcomes essential for institutional 
deployments of NGS technologies. Reporting on such metrics, 
including whether implementation of NGS creates new prob-
lems in delivering effective patient care, should remain a prior-
ity for future studies.
This study was not designed to determine whether the deci-
sion to implement NGS testing was actually sound. Second, for 
these “early adopters,” metrics for outcomes were not yet avail-
able. Rather, in our interviewing this first wave of NGS adopt-
ers, their real-time experiences can instead serve as a guide for 
other institutions or health-care entities giving consideration to 
the value of incorporating genomic medicine into their clinical 
programming, in advance of an extensive evidence base being 
established for the ultimate utility of genomic medicine. By 
also creating an extensive lexicon of key concepts, this study 
helps advance a recommendation by Manolio et al.14 that insti-
tutional efforts to establish genomic medicine programs should 
benefit from collaboration using a more structured sharing of 
best practices. In doing so, this study helps delineate the key 
elements of decision making and implementation, and it can 
serve as a guide for future institutions and health systems 
that are considering offering genomic testing to their patient 
populations.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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